Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lytix Biopharma AS ( (DE:6BG) ) just unveiled an announcement.
Lytix Biopharma has registered a national prospectus in Norway for a subsequent offering of up to 3,333,333 new shares at NOK 9.00 per share, following its recently completed NOK 61 million private placement, potentially adding up to NOK 30 million in gross proceeds. The subsequent offering, which opened on 27 January and runs until 10 February 2026, is targeted at eligible existing shareholders who were not allocated shares in the private placement, providing them with tradable subscription rights on a one-for-one basis for new shares and reinforcing Lytix’s capital base as it advances its clinical-stage oncology pipeline.
More about Lytix Biopharma AS
Lytix Biopharma AS is a clinical-stage biotechnology company based in Oslo, Norway, developing host-defense peptide-derived molecules to stimulate anti-cancer immunity. Its lead candidate, LTX-315, is a first-in-class oncolytic molecule designed to boost immune responses against a broad range of cancer indications, both as a standalone treatment and in combination therapies, supported by a wider pipeline of similar immuno-oncology assets.
Average Trading Volume: 87,740
Current Market Cap: NOK675.8M
For detailed information about 6BG stock, go to TipRanks’ Stock Analysis page.